Drugs / Cerdulatinib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01994382 | Aug 2013 → Dec 2020 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mature T-cell and NK-cell non-Hodgkin lymphoma | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04103060 | Sep 2019 → Nov 2020 | vitiligo | Dermavant Sciences GmbH | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04021082 | Nov 2019 → Dec 2022 | Nodal T-follicular helper cell lymphoma, follicular type, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma +4 | Portola Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase not stated1 trial | ||||||
| — | NCT04757259 | — | B-cell chronic lymphocytic leukemia | Alexion Pharmaceuticals, Inc. | No longer available | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cerdulatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04757259 ↗ |
| Known as | Cerdulatinib Hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL4116008 ↗ |
| Known as | Prt-2070 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4116008 ↗ |
| Known as | PRT062070 | “Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)” NCT04021082 ↗ |
| Known as | RVT-502 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4116008 ↗ |
| Action | Inhibit | “The pharmacodynamics of cerdulatinib, a dual SYK/JAK inhibitor, and associations with tumor response were investigated.” PMID 30333224 ↗ Oct 20183“Tyrosine-protein kinase JAK3 inhibitor” CHEMBL4116008 ↗ “Tyrosine-protein kinase TYK2 inhibitor” CHEMBL4116008 ↗ “Tyrosine-protein kinase JAK1 inhibitor” CHEMBL4116008 ↗ |
| Modality | Small molecule | “Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies” NCT04021082 ↗ |
| Route | Oral | “This is an open-label, Phase 1/2a, multi-dose, multi-center trial of orally administered cerdulatinib assessing safety, tolerability, and pharmacokinetic (PK) parameters...” NCT01994382 ↗ |
| Target | JAK1 | “Tyrosine-protein kinase JAK1 inhibitor” CHEMBL4116008 ↗ |
| Target | JAK3 | “Tyrosine-protein kinase JAK3 inhibitor” CHEMBL4116008 ↗ |
| Target | SYK | “The pharmacodynamics of cerdulatinib, a dual SYK/JAK inhibitor, and associations with tumor response were investigated.” PMID 30333224 ↗ Oct 2018 |
| Target | TYK2 | “Tyrosine-protein kinase TYK2 inhibitor” CHEMBL4116008 ↗ |